Notice of AGM and Annual Report
Guildford, UK - 26 May 2023: Ergomed plc (LSE: ERGO) ("Ergomed" or the "Company"), a company focused on providing specialised services to the pharmaceutical industry, announces that its Annual General Meeting ("AGM") will be held at 85 Gresham Street, London, EC2V 7NQ at 9:30 a.m. on Thursday, 22 June 2023.
Ergomed's Annual Report and Accounts for the year ended 31 December 2022, Notice of AGM and Form of Proxy will be available on the Company's website at www.ergomedplc.com and are being mailed to its shareholders today.
ENDS
Enquiries:
Ergomed plc |
Tel: +44 (0) 1483 402 975 |
Miroslav Reljanović (Executive Chairman) |
|
Jonathan Curtain (Chief Financial Officer) Keith Byrne (Senior Vice President, Capital Markets and Strategy)
|
|
|
|
Numis Securities Limited (Nominated Adviser and Joint Broker) |
Tel: +44 (0) 20 7260 1000 |
Freddie Barnfield / Euan Brown / Jack McLaren |
|
Peel Hunt Securities Limited (Joint Broker) James Steel / Dr Christopher Golden |
Tel: +44 (0) 20 7418 8900
|
|
|
Consilium Strategic Communications -for UK enquiries |
Tel: +44 (0) 20 3709 5700 |
Chris Gardner / Matthew Neal |
ergomed@consilium-comms.com |
About Ergomed plc
Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing services business includes an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand, a full range of high-quality clinical research and trial management services under the Ergomed brand (CRO) and mission-critical regulatory compliance and consulting services under the ADAMAS brand. For further information, visit: http://ergomedplc.com.